NSE: GLAND | BSE: 543245

Slowing Down Stock

Download real time

1474.85 -84.65 (-5.43%)

Near 52W Low of ₹1411.10

556.1K NSE+BSE Volume

NSE 04 Apr, 2025 3:31 PM (IST)

24,299.1

Market Cap

High in industry

0.7

Beta 1Year

Very Low volatility

Tariff Relief

Gland Pharma rises on Thursday as Trump exempts the pharma sector from new tariffs on India See details

Gland Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for GLAND, BSE:543245 Gland Pharma Ltd.

Gland Pharma Ltd.

25 Jan 2022

1474.85

-5.43%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

We believe stock trades at rich valuations of PE of 38.4x and 32.4x for FY23E and FY24E respectively. We, therefore, recommend a HOLD rating on the stock with a target price of Rs 3,575/share.

Gland Pharma Ltd. has an average target of 1710.00 from 2 brokers.

Gland Pharma Ltd.

25 Oct 2021

1474.85

-5.43%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Target

Axis Direct

High competition in injectables generic and increase in raw material prices may impact the company's growth and margins in the upcoming quarters. Furthermore, we believe valuations are rich and thus recommend a HOLD with a target price of Rs 4,000/share

Number of FII/FPI investors increased from 175 to 193 in Dec 2024 qtr.

Gland Pharma Ltd.

24 Oct 2021

1474.85

-5.43%

Robust show despite industry headwinds

Buy: Gland Pharma Ltd.

Target

Motilal Oswal

Gland Pharma (GLAND) delivered in-line 2QFY22 results, led by a strong revenue growth across all geographies, despite increasing cost pressure on account of supply disruptions. With vaccine batch validation completed for Sputnik Lite and 2nd dose, GLAND awaits clarity on the lifting of export restrictions by the government. We lower our EPS estimate by 4%/2% for FY22/FY23, mainly to factor in some delay in commercialization of the Sputnik contract. We remain positive on GLAND based on its a) complex product filings including peptides, longacting injectables for regulated markets, b) commercialization of the Sputnik...

Gland Pharma Ltd.'s price crossed below 50Day SMA today

Gland Pharma Ltd.

08 Sep 2021

1474.85

-5.43%

Axis Annual Analysis:Gland Pharma

Hold: Gland Pharma Ltd.

Axis Direct

We expect revenue and PAT CAGR of 18.2% and 19.7% respectively over FY21-FY24E and recommend a HOLD with TP of Rs 4,100, implying an upside of 3% from CMP.

Gland Pharma Ltd. has lost -22.42% in the last 3 Months

Gland Pharma Ltd.

23 Jul 2021

1474.85

-5.43%

Result Update:Gland Pharma

Hold: Gland Pharma Ltd.

Recommendation Target

Axis Direct

We expect Gland Pharma is well placed to grab upcoming opportunities in the injectables space in the US market, and therefore recommend HOLD with a TP of Rs 4,100/share.

Gland Pharma Ltd.'s price crossed below 50Day SMA today

Gland Pharma Ltd.

21 Jul 2021

1474.85

-5.43%

Complex products/newer markets to fortify growth pace

Buy: Gland Pharma Ltd.

Motilal Oswal

GLAND's 1QFY22 performance was ahead of our expectation, led by robust revenue growth across all geographies. It is progressing well on scaling up manufacturing of the COVID-19 vaccine. It is concurrently developing products/undertaking capex related to complex product as well as enhancing its geographical diversification. We raise our FY22E/FY23E EPS estimate by 8% each to factor in: a) increased reach as well as penetration in the RoW/India markets, b) better outlook for the US market, c) higher offtake of Remdesivir/Enoxaparin, and d)...

Gland Pharma Ltd.'s price crossed below 50Day SMA today

Gland Pharma Ltd.

18 May 2021

1474.85

-5.43%

Result Update:Gland Pharma

Buy: Gland Pharma Ltd.

Target

Axis Direct

We believe Gland Pharma is well placed to grab upcoming opportunities in the injectables space in the US market and therefore recommend a "BUY" with TP of INR 3,200/share.

Gland Pharma Ltd. has an average target of 1710.00 from 2 brokers.

Gland Pharma Ltd.

13 Apr 2021

1474.85

-5.43%

Event Update:Gland Pharma

Buy: Gland Pharma Ltd.

Axis Direct

The Sputnik-V vaccine has been given Emergency Use Authorization by the Indian govt. The vaccine has a proven efficacy rate of 91.5 percent, which is the highest after the candidates of Moderna Inc and Pfizer-BioNTech. The cost of Sputnik V could be in the range of $3.5 per dose.

Gland Pharma Ltd.'s price crossed below 50Day SMA today

Gland Pharma Ltd.

05 Apr 2021, 12:00AM

1474.85

-5.43%

Pick of the Week:05 APR 2021

Buy: Gland Pharma Ltd.

Axis Direct

We recommend BUY on the stock with a target price of Rs 2900.

Number of FII/FPI investors increased from 175 to 193 in Dec 2024 qtr.

Gland Pharma Ltd.

09 Mar 2021

1474.85

-5.43%

Initiating Coverage:Gland Pharma

Gland Pharma Ltd.

Axis Direct

We initiate coverage on Gland Pharma Ltd with a BUY rating and a target price of Rs 2,900 (P/E of 32x for FY23E earnings), implying an upside potential of 15% from the current levels.

Gland Pharma Ltd.'s price crossed below 50Day SMA today

No results found

VOTE: Is Gland Pharma Ltd. worth buying?

203 Votes:

Buy 80.3%

Sell 9.85%

Hold 9.85%

RESEARCH REPORTS

Hold SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf